This is Supreme Court Ruling (Civil Chamber), STS 311/2026, February 25, 2026, presiding judge: Fernando Cerdá Albero, in the appeal and procedural violation case No. 93532021. The ruling addresses the defendant’s standing of the supplier/distributor in liability for defective products when the manufacturer cannot be identified and the supplier fails to notify the injured party within three months (Art. 138.2 TRLGDCU; Art. 3.3 Directive 85/374/EEC). The Chamber upholds the appeal and remands the case to the Provincial Court to issue a new judgment based on the premise that the supplier has standing to be sued.
The judgment recalls (and strictly applies) a rule of enormous practical impact: if the injured party cannot clearly identify the producer of a defective product, the supplier may be “treated as” the producer and held liable as such, unless, within three months of the injured party’s request, the supplier diligently identifies the producer (or the party who supplied the product to them). In sectors with complex supply chains and multinational groups (medical devices, pharmaceuticals, automotive, electronics, etc.), the risk of being sued as the “manufacturer” for failing to clarify in a timely manner who manufactured the product is real. For insurers, this affects risk allocation (who is the “target” insured party in the claim), recovery strategy, and the early management of pre-litigation claims.
The Dispute
The litigation arises from injuries sustained following the implantation of a metal-on-metal hip prosthesis (BHR model) marketed under the Smith & Nephew brand. The patient is seeking compensation and has filed a lawsuit against the group’s Spanish subsidiary (Smith & Nephew S.A.), which he holds liable.
The defendant company maintains that it is not the manufacturer of the product (that would be another company within the same group), but merely a supplier/distributor. Here lies the crux of the case: Article 138.2 of the TRLGDCU provides that, if the producer cannot be identified, the supplier shall be considered the producer unless, within three months, it discloses to the injured party the identity of the producer (or of the party that supplied the product). The question is, therefore, very specific: could the patient “perfectly” identify the manufacturer on his own, or— —was there reasonable confusion that required the supplier to clarify the matter in a timely manner?
Relevant facts and course of the lawsuit
According to the established facts, an implant was placed in 2009; following checkups and tests showing abnormal metal levels, removal was prescribed in 2014 in accordance with clinical recommendations; in 2015, the prosthesis was replaced and the levels returned to normal.
Judicial proceedings: (i) the Court partially upheld the claim and ruled against the Spanish supplier, among other reasons, because it failed to identify the manufacturer within the statutory time limit; (ii) the Provincial Court of Appeal reversed the decision and dismissed the claim, finding that the manufacturer could be identified using documentation provided by the plaintiff himself and that, therefore, the supplier lacked standing to be sued; (iii) the Supreme Court corrects that conclusion and orders a new judgment to be issued on the grounds that the supplier does have standing to be sued since the identity of the manufacturer was not clarified within the prescribed time limit.
The “equating” of the supplier with the producer
The regime of liability for defective products (TRLGDCU) is based on a simple idea: whoever puts an unsafe product into circulation must be liable for damages. The general rule points to the producer (manufacturer, EU importer, or whoever presents themselves as such through their brand). But the legislature recognizes that, in practice, the consumer may encounter a corporate “maze” (brands, subsidiaries, importers, distributors).
To prevent this complexity from leaving the injured party without a “clear” defendant, Article 138.2 of the TRLGDCU introduces a subrogation mechanism: if the producer cannot be identified, the supplier (who supplies or distributes the product on the market) shall be considered the producer, unless within three months they disclose to the injured party the identity of the producer (or of the party who supplied the product to them). The Supreme Court summarizes the requirements as follows: (1) the producer is not identifiable by the injured party; (2) there is a demand or claim against the supplier; and (3) the supplier does not identify the producer within the time limit.
A key nuance is when the time limit begins to run: although the TRLGDCU does not expressly set the starting date, the ruling assumes that it must be calculated from the moment the supplier receives the request from the injured party. And it is not enough to simply deny “I am not the manufacturer”: Directive 85/374/EEC (Art. 3.3)—as interpreted by the CJEU—requires the supplier to provide information on its own initiative and in a diligent manner regarding who the producer is or who its own supplier is.
The Supreme Court’s reasoning
-
Procedural violation: “manifest error” due to an illogical conclusion
The Provincial Court had asserted that the producer was “perfectly identifiable” because an official document mentioned a specific company within the group as the manufacturer. The Supreme Court, however, reviews the Provincial Court’s own reasoning and notes an obvious contradiction: the documentation in question lists at least three possible “manufacturers” (a Spanish company domiciled in Barcelona; a British PLC headquartered in London; and a British Ltd with a different name). Given this scenario, the Supreme Court finds it illogical and unreasonable to conclude that the manufacturer was unequivocal, which falls under constitutional doctrine regarding decisions affected by “manifest error” and, therefore, constitutes a violation of the right to effective judicial protection (Art. 24 CE).
-
Appeal: strict application of Art. 138.2 TRLGDCU and prior doctrine
In its ruling on appeal, the Supreme Court places the case within an established line of reasoning in prosthesis-related litigation: when there is reasonable confusion regarding the identity of the manufacturer within groups comprising multiple companies, the legal system provides a solution: either the supplier identifies the manufacturer in a timely manner, or it may be held liable as if it were the manufacturer itself. The ruling expressly aligns with its own doctrine (Supreme Court Rulings 34/2020 and 448/2020, Plenary Session) and with the CJEU (December 2, 2009, Case C-358/08), which requires the supplier to do more than issue a generic denial: it must diligently disclose the identity of the manufacturer or its own supplier.
Applying this rule, the Supreme Court notes that the patient filed out-of-court claims and that the supplier had “repeated opportunities” to clarify: “I am not the manufacturer” and, above all, who is. Instead, its responses remained ambiguous (for example, it referred to “Smith & Nephew components” and requested documentation to “evaluate” the claim) without identifying the manufacturer within the legal deadline. The identification only occurs, as recorded, in the answer to the complaint (September 2016), that is, too late to benefit from the exemption under Art. 138.2 TRLGDCU. Consequence: Smith & Nephew S.A. has standing to be sued under the defective products regime.
Important: The Supreme Court does not set the compensation amount nor does it definitively rule on the defendant’s civil liability. What it does is “clear” the proceedings of a prior obstacle (the lack of standing to be sued found by the Regional Court) and remands the case for a new judgment to be issued on the merits, based on the premise that the supplier has standing.
Why this ruling is particularly interesting for insurers
From an insurer’s perspective, the ruling is significant because it transforms a mere procedural detail (who has standing to be sued) into a lever that can shift the risk from the manufacturer to the distributor and, thereby, alter the landscape of coverage and recovery.
- The “insured risk” can shift to the wrong link in the chain. A distributor with a general liability or product liability policy may end up being held liable “as a producer” if they do not properly manage identification. This increases exposure in distribution and import accounts, especially in regulated sectors (healthcare, pharmaceuticals) and among multinational groups.
- The claim is decided before litigation. The critical point is not just the lawsuit, but the out-of-court claim: from that moment, the 3-month clock starts ticking. For insurers, this reinforces the importance of early notification and response protocols for consumer/patient claims.
- Document management and traceability. The ruling rewards diligence: having traceability (batches, UDIs, delivery notes, supply contracts) and a procedure that allows for the rapid identification of the manufacturer/importer reduces the likelihood of “assimilation.”
- Impact on recoveries and co-insurance. If the supplier is named as the primary defendant, recovery against the actual manufacturer (often foreign) can become complicated. It is advisable to plan strategies in advance: choice of jurisdiction, cooperation among group insurers, and contractual indemnity mechanisms.
- Relevance to policy wording. In product liability policies, it is advisable to review definitions of “product,” “insured,” “supplier/importer,” and conditions regarding cooperation and mitigation. A delayed or ambiguous response to a claimant may become the triggering event for liability.
Conclusion
This ruling highlights the importance of properly mapping out the parties responsible in a claim.
At the Insurance Department of Belzuz Abogados, S.L.P., as specialists in Medical Malpractice and Insurance Law, we believe this ruling is of particular relevance to attorneys, insurers, healthcare professionals, and hospital administrators.